Chemomab Therapeutics Ltd. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Chemomab Therapeutics Ltd. (CMMB) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $0.06 per share for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-23.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-03-23
- Chemomab Therapeutics Ltd. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2020 was $0.08.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|
| 2025-12-31 | $0.06 20-F · filed 2026-03-23 | ||
| 2025-06-30 | $0.06 6-K · filed 2025-08-14 | ||
| 2024-12-31 | $0.03 20-F · filed 2026-03-23 | ||
| 2023-12-31 | $0.07 20-F · filed 2026-03-23 | ||
| 2022-12-31 | $0.16 20-F · filed 2025-04-04 | ||
| 2021-12-31 | $0.62 20-F · filed 2024-03-28 | ||
| 2021-09-30 | $27.26 10-Q · filed 2021-11-12 | ||
| 2021-06-30 | $27.26 10-Q · filed 2021-08-13 | ||
| 2020-12-31 | $0.08 10-K · filed 2022-03-30 |